

Journal of Applicable Chemistry

2014, 3 (4): 1468-1474 (International Peer Reviewed Journal)



Synthesis, Antibacterial and Antifungal Activity of Flavanones and Chalcones Derived From 2-Hydroxy-Acetonaphthone

Birendra kumar¹, Binita Kumari¹, Neha Singh¹, B. Ram² and B. Balram²

Department of Chemistry, Gaya College, Gaya, 823001(Bihar), INDIA
Green Evolution Laboratories, Wangapally Village, Nalgonda, 500085, Telangana State, INDIA

Email: kumarbirendra0619@gmail.com

Accepted on 27th June 2014

ABSTRACT

Eleven new flavanones **1a-1k** and three new chalcones **1l-n** were prepared from commercially available 2-Hydroxy-acetonaphthone. All the newly synthesized compounds were characterized by ¹H NMR, MS and IR data. These compounds were screened for their antibacterial and antifungal activity against Gram-positive (Bacillus subtilis and Staphylococcus aureus), Gram-negative (Escherichia coli and Salmonella typhii), Aspergillus niger and Candida albicans organisms by measuring zone of inhibition. Among the synthesized flavanones and chalcones **1c**, **1d**, **1e**, **1f**, **1k**, **1l** and **1m** compounds bearing substitutions such as fluorine, trifluoromethyl, trifluromethoxy, di-fluoro and pyridine ring has shown good activity against all the tested bacteria and fungal strains.

Keywords: Flavanones, Chalcones, 2-Hydroxy-Acetonaphthone, Synthesis, Anti-bacterial activity.

INTRODUCTION

Flavonoids, a class of plant secondary metabolites, are polyphenols based around a phenylbenzopyrone structure [1,2]. According to their different skeletons, they are categorized into flavones, flavanones, chalcones, flavonols, isoflavones and aurones, *etc.* [3]. Flavanone is an important polyphenolic compound which is widely used to manufacture varied medicines [4-9]. The flavanones are mainly distributed in citrus fruits and have attracted considerable attention because they possess antioxidant effect, potent inhibition of cancer cell proliferation, and cytotoxic activity [10-13].

Chalcones, analogs of 1,3-diarylprop-2-en-1-one, of plant origin are known1. Chalcones present great interest as compounds exhibiting antimalarial [14], antibacterial [15], antifibrogenic [16], anticancer [17], antitrichomonal [18], anti-inflammatory [19], antileishmanial [20], cytotoxic and antitrypanosoma cruzi [21-22] activities.

In spite of the large number of antibiotics and chemotherapeutics available for medical use, the emergence of old and new antibiotic resistant bacterial strains in the last decades constitutes a substantial need for development of new antibacterial and antifungal agents with divergent and unique structure and with a mechanism of action possibly different from that of existing antimicrobial agents [23, 24]. Encouraged by

the various biological activities associated with chalcones and flavanone derivatives we describe herein the synthesis, characterization and antibacterial activity of some new flavanone and chalcone derivatives derived from 2-Hydroxy- Acetonaphthone.

MATERIALS AND METHODS

Chemical and solvents used were purchased either from Fluka or Merck. All the reagents were of analytical grade. Thin-layer chromatography (TLC) was performed on E.Merck AL silica gel 60 F254 plates and visualized under UV light. The IR spectra were recorded on a Perkin Elmer FT-IR spectrometer. The ¹H NMR spectra were recorded in CDCl₃ on a Varian EM-360 spectrometer (400MHz). The ¹³C NMR spectra recorded in CDCl₃ on a Varian EM-360 spectrometer operating at 100MHz. All the chemical shifts were reported in δ (ppm) using TMS as an internal standard. The mass spectra were recorded on Agilent ion trap MS.

General Procedure For The Preparation of 2,3-dihydro-1H-benzo[f]chromen-1-one derivatives (1a-1k) and chalcone derivatives (11 - 1n): To a ethanol solution containing 2-Hydroxy-acetonaphthone (200 mg, 0.538 mmol) was added appropriate aldehydes (a-n, 0.538 mmol) followed by aqueous; 60% KOH (w/v) (0.5 mL). The contents were stirred at room temperature for 24h under nitrogen atmosphere. The reaction mixture was poured into water, cooled to 10-15 °C and acidified to pH = 1-2 and extracted with ethyl acetate. The organic layer was washed with brine solution, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure, to obtain the crude compounds. The crude compounds were purified by column chromatography using silica gel (100-200 mesh). Yields of the products varied between 70 and 93%.

3-(4-bromophenyl)-2,3-dihydrobenzo[f]chromen-1-one (1a): Pale yellow solid, Yield: 84%; m.p: 88-89 °C; IR (KBr): v_{max} 3053, 2973, 1740, 1653, 1619, 1596, 1565, 1513, 1489, 1460, 1437, 1398, 1373, 1339, 1279, 1234, 1206, 1150, 1124, 1072, 1046, 1006, 957, 934, 898, 830, 807, 753, 695, 710, 679, 660, 641 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 9.50 (s, 1H), 7.96 (d, 1H, *J* = 16.0 Hz), 7.78 (d, 1H, *J* = 8.2 Hz), 7.66 (t, 1H, *J* = 7.8 Hz), 7.58-7.56 (m, 2H), 7.46 (t, 1H, *J* = 7.6 Hz), 7.40 (d, 2H, *J* = 5.8 Hz), 7.18 (d, 2H, *J* = 5.8 Hz), 5.62 (dd, 1H, *J* = 2.0, 8.0 Hz), 3.15 (dd, 1H, *J* = 8.0, 16.0 Hz), 2.94 (dd, 1H, *J* = 2.0, 8.0 Hz); ESI-MS: m/z, 351, 353 (M-1).

3-(4-chloroophenyl)-2,3-dihydrobenzo[f]chromen-1-one (1b): Pale yellow solid, Yield: 84%; m.p: 88-89 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.48 (s, 1H), 7.94 (d, 1H, *J* = 16.0 Hz), 7.76 (d, 1H, *J* = 8.2 Hz), 7.66 (t, 1H, *J* = 7.8 Hz), 7.56-7.52 (m, 2H), 7.46 (t, 1H, *J* = 7.6 Hz), 7.40 (d, 2H, *J* = 5.8 Hz), 7.18 (d, 2H, *J* = 5.8 Hz), 5.62 (dd, 1H, *J* = 2.0, 8.0 Hz), 3.15 (dd, 1H, *J* = 8.0, 16.0 Hz), 2.94 (dd, 1H, *J* = 2.0, 8.0 Hz); ESI-MS: m/z, 309.2 (M+1).

3-(4-fluorophenyl)-2,3-dihydrobenzo[f]chromen-1-one (1c): Yellow solid, Yield: 82%; m.p: 92-94 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.48 (s, 1H), 7.94 (d, 1H, *J* = 16.0 Hz), 7.76 (d, 1H, *J* = 8.2 Hz), 7.66 (t, 1H, *J* = 7.8 Hz), 7.56-7.52 (m, 2H), 7.46 (t, 1H, *J* = 7.6 Hz), 7.40 (d, 2H, *J* = 5.8 Hz), 7.18 (d, 2H, *J* = 5.8 Hz), 5.62 (dd, 1H, *J* = 2.0, 8.0 Hz), 3.15 (dd, 1H, *J* = 8.0, 16.0 Hz), 2.94 (dd, 1H, *J* = 2.0, 8.0 Hz); ESI-MS: m/z, 309.2 (M+1).

3-(4-(trifluoromethyl)phenyl)-2,3-dihydrobenzo[f]chromen-1-one (1d): Yellow solid, Yield: 80%; m.p: 102-104 °C; IR (KBr): v_{max} 3081, 1665, 1620, 1597, 1566, 1513, 1462, 1438, 1424, 1399, 1372, 1324, 1280, 1237, 1208, 1155, 1120, 1064, 1007, 950, 900, 848, 830, 756, 730, 699, 658, 614 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 9.48 (d, 1H, J = 8.0 Hz), 7.98 (d, 1H, J = 7.8 Hz), 7.74-7.72 (m, 2H), 7.68-7.64 (m, 3H), 7.46 (t, 1H, J = 8.0 Hz), 7.20 (d, 1H, J = 8.0 Hz), 5.64 – 5.62 (m, 1H), 3.24 - 3.18 (m, 1H), 3.06-3.0 (m, 1H); ESI-MS: m/z, 341.1 (M+1).

2,3-dihydro-3-(4-(trifluoromethoxy)phenyl)benzo[f]chromen-1-one (1e): Yellow solid, Yield: 88%; m.p: 111 - 112 °C; IR (KBr): v_{max} 3118, 3079, 1663, 1618, 1595, 1564, 1511, 1459, 1435, 1392, 1370, 1261, 1199, 1145, 1121, 1069, 1045, 1017, 1001, 953, 922, 898, 853, 829, 783, 735, 677, 630 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 9.62 (d, 1H, J = 8.2 Hz), 7.98 (d, 1H, J = 8.8 Hz), 7.78 (d, 1H, J = 8.4 Hz), 7.66 (t, 1H, J = 7.8 Hz), 7.58 - 7.54 (m, 2H), 7.46 (t, 1H, J = 7.8 Hz), 7.36-7.34 (m, 1H), 7.18 (d, 1H, J = 7.8 Hz), 5.18 (dd, 1H, J = 2.0, 8.2 Hz), 3.22 - 3.20 (m, 1H), 3.02 - 2.98 (m,1H); ESI-MS: m/z, 357.1 (M-1).

2,3-dihydro-3-(3-(trifluoromethyl)phenyl)benzo[f]chromen-1-one (1f): Pale yellow solid, Yield: 92%; m.p: 78-79 °C; IR (KBr): v_{max} 3086, 1661, 1598, 1556, 1512, 1437, 1453, 1400, 1327, 1371, 1286, 1240, 1212, 1150, 1117, 1074, 1050, 1021, 1008, 977, 907, 885, 825, 803, 786, 758, 740, 699, 660, 618 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 9.64 (d, 1H, J = 8.2 Hz), 7.98 (d, 1H, J = 8.8 Hz), 7.86- 7.78 (m, 2H), 7.74- 7.66 (m, 3H), 7.58 (t, 1H, J = 7.8 Hz), 7.46 (t, 1H, J = 7.8 Hz), 7.20 (d, 1H, J = 7.8 Hz), 5.52 (dd, 1H, J = 2.0, 7.8 Hz), 3.20 (dd, 1H, J = 2.0, 8.6 Hz), 3.0 (dd, 1H, J = 2.0, 8.0 Hz); ESI-MS: m/z, 341.1 (M-1).

2,3-dihydro-3-(4-methoxyphenyl)benzo[f]chromen-1-one (1g): Off white solid; Yield: 84%; m.p: 98 - 99 °C; ¹H NMR (400 MHz, CDCl₃): δ 9.38 (s, 1H), 7.94 (d, 1H, J = 16.0 Hz), 7.72 (d, 1H, J = 8.2 Hz), 7.62 (t, 1H, J = 7.8 Hz), 7.54-7.50 (m, 2H), 7.44 (t, 1H, J = 7.6 Hz), 7.38 (d, 2H, J = 5.8 Hz), 7.12 (d, 2H, J = 5.8 Hz), 5.62 (dd, 1H, J = 2.0, 8.0 Hz), 3.15 (dd, 1H, J = 8.0, 16.0 Hz), 2.94 (dd, 1H, J = 2.0, 8.0 Hz); ESI-MS: m/z, 351, 353 (M-1).

3-(4-ethoxy-3-methoxyphenyl)-2,3-dihydro-1H-benzo[f]chromen-1-one (**1h**): Yellow oily liquid; Yield: 140 mg, 75%; ¹H NMR (400 MHz, CDCl₃): ð 1.35 (t, 3H, J = 6.8 Hz), 2.85 (dd, 1H, J = 2.0, 16.0 Hz), 3.45 (t, 1H, J = 16 Hz), 3.80 (s, 3H), 4.05 (q, 2H, J = 6.6 Hz), 5.70 (dd, 1H, J = 2.0, 16.0 Hz), 6.95 (d, 1H, J = 16.0 Hz), 7.05 (d, 1H, J = 8.0 Hz), 7.20 (s, 1H), 7.25 (d, 1H, J = 16.0 Hz), 7.45 (t, 1H, J = 20.0 Hz), 7.65 (t, 1H, J = 20.0 Hz), 7.90 (d, 1H, J = 8.0 Hz), 8.15 (d, 1H, J = 16.0 Hz), 9.38 (d, 1H, J = 8.0 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 14.61, 56.21, 42.18, 64.86, 82.77, 109.03, 111.38, 112.66, 117.74, 118.84, 124.48, 125.03, 128.26, 128.73, 129.53, 129.74, 131.18, 134.62, 149.53, 150.13, 155.71, 196.73; EI MS: m/z (rel.abund.%) 349.0 (M⁺, 100).

2,3-dihydro-3-(3-methoxy-4-propoxyphenyl)benzo[f]chromen-1-one (1i): Yellow viscous liquid; Yield: 151 mg, 78%; ¹H NMR (400 MHz, CDCl₃): ð 1.00 (t, 3H, J = 6.8 Hz), 1.75 (q, 2H, J = 6.8 Hz), 2.85 (dd, 1H, J = 2.0, 16.0 Hz), 3.45 (t, 1H, J = 16 Hz), 3.80 (s, 3H), 3.95 (t, 2H, J = 6.6 Hz), 5.70 (dd, 1H, J = 2.0, 16.0 Hz), 6.95 (d, 1H, J = 16.0 Hz), 7.05 (d, 1H, J = 8.0 Hz), 7.20 (s, 1H), 7.25 (d, 1H, J = 16.0 Hz), 7.45 (t, 1H, J = 20.0 Hz), 7.65 (t, 1H, J = 20.0 Hz), 7.90 (d, 1H, J = 8.0 Hz), 8.15 (d, 1H, J = 16.0 Hz), 9.38 (d, 1H, J = 8.0 Hz); ¹³C NMR (100 MHz, CDCl₃): δ 10.37, 22.06, 42.18, 56.03, 70.54, 82.86, 109.03, 112.68, 114.32, 117.76, 118.83, 124.47, 125.06, 128.33, 128.73, 129.58, 129.68, 131.16, 134.74, 149.53, 150.08, 155.86, 196.69. EI MS: m/z (rel.abund.%) 363.0 (M⁺, 100).

3-(4-tert-butylphenyl)-2,3-dihydrobenzo[f]chromen-1-one: (1j): Brown solid, Yield: 70%; m.p: 69-70 °C; IR (KBr): v_{max} 3118, 3035, 2957, 2901, 2865, 1964, 1923, 1895, 1851, 1815, 1665, 1615, 1593, 1561, 1511, 1456, 1432, 1392, 1366, 1277, 1234, 1204, 1141, 1119, 1068, 1044, 1018, 997, 953, 899, 870, 828, 751, 672, 652 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 9.54 (d, 1H, J = 8.4 Hz), 7.96 (d, 1H, J = 8.6 Hz), 7.76 (d, 1H, J = 8.4 Hz), 7.66 (t, 1H, J = 7.8 Hz), 7.52 - 7.46 (m, 5H), 7.18 (d, 1H, J = 7.8 Hz), 5.66 (m, 1H), 3.30 - 3.20 (m, 1H), 2.98 (dd, 1H, J = 2.0, 8.0 Hz); ESI-MS: m/z, 329.1 (M+1).

2,3-dihydro-3-(pyridin-4-yl)benzo[f]chromen-1-one (1k): Pale yellow solid, Yield: 78%; m.p: 76-77 °C; IR (KBr): v_{max} 3046, 2973, 1660, 1619, 1594, 1569, 1511, 1480, 1459, 1434, 1398, 1370, 1344, 1279, 1234, 1207, 1157, 1143, 1121, 1081, 1047, 1020, 965, 949, 897, 857, 821, 798, 755, 709, 644, 614 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 9.50 (d, 1H, J = 8.6 Hz), 8.82 (br.s, 1H), 8.52 (br.s, 1H), 8.0-7.96 (m, 1H), 7.92-7.90 (m, 1H), 7.84-7.80 (m, 1H), 7.70-7.65 (m, 1H), 7.50-7.48 (m, 2H), 7.44-7.42 (m, 1H), 5.66 (dd, 1H, J = 2.0, 7.8 Hz), 3.30 - 3.18 (m, 1H), 3.10 - 3.06 (m, 1H); ESI-MS: m/z, 276.1 (M-1).

www.joac.info

(E)-3-(2-(trifluoromethyl)phenyl)-1-(2-hydroxynaphthalen-1-yl)prop-2-en-1-one (11): White solid, Yield: 92%; m.p: 118-119 °C; IR (KBr): v_{max} 2971, 1740, 1662, 1637, 1618, 1598, 1566, 1512, 1483, 1460, 1407, 1371, 1336, 1312, 1286, 1239, 1167, 1105, 1057, 1035, 995, 957, 899, 838, 789, 758, 726, 712, 726, 649 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 12.60 (s, 1H), 8.26 (d, 1H, *J* = 16.2 Hz), 8.04 (d, 1H, *J* = 8.4 Hz), 7.94 (d, 1H, *J* = 8.4 Hz), 7.84 (d, 1H, *J* = 8.2 Hz), 7.78 (d, 1H, *J* = 7.8 Hz), 7.60-7.50 (m, 3H), 7.46-7.40 (m, 1H), 7.20 (d, 1H, *J* = 16.0 Hz); ESI-MS: m/z, 341.1 (M+1).

(E)-3-(2,4-difluorophenyl)-1-(2-hydroxynaphthalen-1-yl)prop-2-en-1-one (1m): White solid, Yield: 84%; m.p: 100-101 °C; IR (KBr): v_{max} 3076, 1658, 1602, 1570, 1504, 1468, 1426, 1369, 1341, 1275, 1232, 1207, 1183, 1141, 1101, 1043, 1022, 998, 970, 885, 820, 756, 730, 694, 647, 612 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 12.66 (s, 1H), 8.08-8.04 (m, 1H), 7.98-7.92 (m, 2H), 7.84-7.82 (m, 1H), 7.62-7.56 (m, 3H), 7.44-7.38 (m, 1H), 7.18 (d, 1H, *J* = 15.8 Hz), 6.98-6.88 (m, 2H); ESI-MS: m/z, 309.1 (M+1).

(E)-3-(2,4-dimethoxyphenyl)-1-(2-hydroxynaphthalen-1-yl)prop-2-en-1-one (1n): White solid, Yield: 82%; m.p: 121-122 °C; IR (KBr): v_{max} 3005, 1659, 1629, 1595, 1497, 1464, 1410, 1370, 1332, 1315, 1279, 1233, 1172, 1127, 1107, 1039, 1002, 989, 966, 942, 888, 844, 816, 801, 735, 715, 649 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 12.58 (s, 1H), 8.22-8.12 (m, 2H), 7.94 (d, 1H, *J* = 8.4 Hz), 7.82 (d, 1H, *J* = 8.4 Hz), 7.64 (d, 1H, *J* = 15.2 Hz), 7.54-7.50 (m, 1H), 7.42-7.40 (m, 1H), 7.20 (d, 1H, *J* = 8.2 Hz), 7.01 (d, 1H, *J* = 7.8 Hz), 6.96-6.88 (m, 2H), 3.94 (s, 3H), 3.78 (s, 3H); ESI-MS: m/z, 333.1 (M+1).

Antibacterial and Antifungal Bioassay: The antibacterial activity of all the synthesized compounds (1a- 1n) were examined against Gram-positive (*Bacillus subtilis* and *Staphylococcus aureus*) and Gram-negative (*Escherichia coli* and *Salmonella typhii*) organisms by measuring zone of inhibition. The antibacterial activity was performed by Agar diffusion method at the concentration level of 250μ g/mL. Ciprofloxacin was used as standard drug at a concentration of 250μ g/mL. Nutrient agar was used as culture media and DMSO was used as solvent control [25-27]. The results of the antibacterial activity are shown in table 1.

The antifungal activity of all the synthesized compounds (**1a- 1n**) were examined against *Aspergillus niger* and *Candida albicans* by measuring zone of inhibition. The antifungal activity was performed by Agar diffusion method at the concentration level of 250μ g/mL. Ketoconazole was used as standard drug at a concentration of 250μ g/mL. Sabouraud dextrose agar was used as culture media and DMF was used as solvent control [27,28]. The results of the antifungal activity are shown in table 1.

Compound no.	Gram negative bacteria		Gram positive bacteria		Fungi				
	E. coli	S.typhi	B.subtilis	S.aureus	A. niger	C. albicans			
	Zone of inhibition expressed in mm								
1a	-	-	-	-	-	-			
1b	-	-	-	-	-	-			
1c	17	14	16	15	16	15			
1d	17	14	15	14	16	15			
1e	18	13	15	14	18	16			
1f	18	12	16	15	18	14			
1g	11	10	10	10	12	9			
1h	11	10	10	10	12	10			
1i	12	9	9	9	10	9			
1j	12	9	10	9	11	8			
1k	17	13	14	12	16	13			
11	18	13	15	13	15	14			
1m	16	12	13	13	15	14			


Table 1: Results of Antibacterial and Antifungal activity of Compounds 1a-1n

1n	10	8	11	9	11	8
Ciprofloxacin	19	15	16	15		
Ketoconazole					18	16

Standard drug concentration: 250µg mL⁻¹; "--_ No Activity

RESULTS AND DISCUSSION

The synthesis of new flavanone and chalcone derivatives is depicted in scheme 1. All the synthesized flavanone compounds **1a-n** were purified by successive recrystallisation using ethanol. The reaction of 2-Hydroxy-acetonaphthone with various benzaldehydes (a-n) in presence of aqueous 60% ethanolic KOH (w/v) at room temperature for 24 h resulted in the formation of flavanone derivatives 1a - 1k. It is observed that the reaction of 2-Hydroxy-acetonaphthone with benzaldehydes such as 2-trifluoromethyl benzaldehyde, 2,4-difluoro benzaldehyde and 2,4-dimethoxy benzaldehyde produced corresponding chalcone derivatives 11 - 1n. The purity of the synthesized compounds was checked by performing TLC. The structures of the synthesized compounds were determined on the basis of their ¹HNMR, FTIR and MS data. In general, the ¹H NMR spectrum of the flavanone compounds 4a-k, the proton signal at 5.62 (dd, J = 4.0, 8.0 Hz), 3.15 (dd. J = 8.0, 16.0 Hz), and 2.94 (dd. J = 2.0, 8.0 Hz) showed a characteristic for H-2. H-3ax, and H-3eq a typical ABX system for a flavanone structure. The remaining aromatic proton signals appeared in the expected region. As a representative example, the ¹HNMR spectra of the synthesized chalcone compounds 4l, the protons of α , β -unsaturated carbonyl compounds have given two doublets in the range of 8.26 (δ , ppm) for H α and 7.20 (δ , ppm) for H_{β} indicating the formation of chalcone derivative. The formation of the chalcone derivatives was further confirmed by IR spectra, compounds showed the presence of vC=O stretching bands at 1647-1664 cm⁻¹ and vC=C stretching frequencies at 1579-1600 cm⁻¹ corresponding to α , β -unsaturated carbonyl compounds.



Scheme 1: Reagents and Conditions: a)aqueous 60% KOH (w/v), Ethanol, room temp. 24h

The results of the antimicrobial and antifungal activity from table 1 is as follows-

All the synthesized flavanones **1a-k** and chalcones **1l-n** have shown mild to good activity against the tested bacterial and fungal strains. Among the synthesized flavanones and chalcones **1c**, **1d**, **1e**, **1f**, **1k**, **1l** and **1m**

www.joac.info

compounds bearing substitutions such as fluorine, trifluoromethyl, trifluromethoxy, di-fluoro and pyridine ring has shown good activity against all the tested bacteria and fungal strains.

APPLICATIONS

The newly synthesized flavanones and chalcones (**1a-n**) were screened for their antibacterial and antifungal activity and the results revealed that most of the compounds showed mild to good activity. Thus, a further structural modification of this scaffold may lead to a promising antibacterial and fungal pharmacophore.

CONCLUSIONS

In summary, the present paper describes the synthesis, characterization, antibacterial and antifungal activity of flavanone and chalcone derivatives (1a-n). Among the synthesized flavanones and chalcones 1c, 1d, 1e, 1f, 1k, 1l and 1m compounds bearing substitutions such as fluorine, trifluoromethyl, trifluromethoxy, di-fluoro and pyridine ring has shown good activity against all the tested bacteria and fungi.

REFERENCES

- [1] D. Grassi, G. Desideri, G. Croce, S.Tiberti, A. Aggio, C. Ferri. *Curr. Pharm. Design.*, **2009**, 10, 1072–1084.
- [2] J.B. Harborne, C.A. Williams. *Phytochemistry.*, **2000**, 55, 481–504.
- [3] L. Bravo, *Nutr. Rev.*, **1986**, 56, 317–333.
- [4] R. Li R, G.L. Kenyon, F.E. Cohen, X. Chen, B. Gong, J.N. Dominguez, E. Davidson, G. Kurzban, R.E. Miller, E.O. Nuzum. J. Med. Chem., 1995, 38, 5031.
- [5] A. Dinkova-Kostova, T.C. Abeygu Nawardana, P. Talaley. J. Med. Chem., 1998, 41, 5278.
- [6] J.F. Ballesteros, M.J. Sanz, A. Ubeda, M.A. Miranda, S. Iborra, M. Payá, M.J. Alcaraz. J. Med. Chem., 1995, 38, 2794.
- [7] J.R. Dimmock, N.M. Kandepu, M. Hetherington, J.W. Quail, U. Pugazhenthi, A.M. Sudom, M. Chamankhah, P. Rose, E. Pass, T.M. Allen. *J. Med. Chem.*, **1998**, 41, 1014.
- [8] M.D. Ankhiwala. J. Indian Chem. Soc., **1990**, 67, 913.
- [9] A. Mantas, E. Deretey, F.H. Ferretti, M.R. Estrada, I.G. Csizmadia. J. Mole. Struct.(Theochem.), 2000, 504, 171.
- [10] J.B. Harborne. *The Flavonoids*; Chapman & Hall: London, U. K., 1994; p 406.
- [11] J.B. Harborne, C.A. Williams. Nat. Prod. Rep. 2001, 18, 310.
- [12] R.J. Nijveldt, E. Nood, D. Hoorn, P.G. Boelens, K. Norren, P. Leeuwen. Am. J. Clin. Nutr. 2001, 74, 418.
- [13] K.E. Heim, A.R. Tagliaferro, D.J. Bobilya. J. Nutr.Biochem. 2002, 13, 572.
- [14] E. Hijova, Bratisl Lek Listy., 2006, 107(3): 80-84.
- [15] M. Liu, P. Wilairat, G. Mei-Lin. J.Med.Chem., 2001, 44, 4443-4452.
- [16] V. Opletalova. Cesk.Slov.Farm., 2000, 49:278-284.
- [17] S.H. Lee, J.X. Nan, Y.Z. Zhao, S.W. Woo, E.J. Park, T.H. Kang, G.S. Seo, Y.C. Kim, D.H. Sohn. *Planta. Med.*, **2003**, 69, 990-994.
- [18] M.T. Konieczny, W. Konieczny, M. Sabisz, A. Skladanowski, R. Wakiec, E. Augustynowicz-Kopec, Z. Zwolska, *Chem. Pharm. Bull.*, 2007, 55: 817-820.
- [19] A.O. Oyedapo, V.O. Mankanju, C.O. Adewunmi, E.O. Iwalewa, T.K. Adenowo. *Afr.J.Trad.*, CAM 2004, 1:55-62.
- [20] F. Jin, X.Y. Jin, Y.L. Jin, D.W. Sohn, S.A. Kim, D.H. Sohn, Y.C. Kim, H.S. Kim. *Arch.Pharm.Res.*, **2007**, 30(11), 1359-1367.

- [21] T. Narender, T. Khaliq, Shweta, Nishi, N. Goyal, S.Gupta. *Bioorg.Med.Chem.*, **2005**, 13, 543-6550.
- [22] J.C. Aponte, M. Verastegui, E. Malaga, M. Zimic, M. Quiliano, A.J. Vaisberg, R.H. Gilman, G.B. Hammond. *J.Med.Chem*, **2008**, 51, 6230-6234.
- [23] I. Chopra, C. Schofield, M. Everett, A. O'Neill, K. Miller, M. Wilcox, J.-M. Fre`re, M. Dawson, L. Czaplewski, U. Urleb, P. Courvalin. *Lancet Infect. Dis.*, **2008**, 8, 133–139.
- [24] A. Khalafi-Nezhad, M.N.S. Rad, H. Mohabatkar, Z. Asrari, B. Hemmateenejad. *Bioorg. Med. Chem.*, 2005, 13, 1931-1938.
- [25] Daniela Batovska, Stoyan Parushev, Bistra Stamboliyska, Iva Tsvetkova, Mariana Ninova, Hristo Najdenski. *Eur.J.Med.Chem.*, **2009**, 44, 2211-2218.
- [26] V. Tomar, G. Bhattacharjee, Kamaluddin, Ashok Kumar. *Bioorg. Med. Chem. Lett.*, 2007, 17, 5321–5324.
- [27] Y. Rajendra Prasad, A. Lakshmana Rao, R. Rambabu. *E.J. Chem.*, 2008, 5: 461-466.
- [28] K.L. Lahtchev, D.I. Batovska, P. St. Parushev, V.M. Ubiyvovk, A.A. Sibirny, *Eur. J.Med. Chem.*, **2008**, 43, 220-2228.
- [29] Rajasekhar M, Prasad Reddy, T.S.V, Anima Sunil Dadhich. Synthesis and Antimicrobial Activity of Novel Chalcone Analogues Bearing 2-Furan Trifluoromethyl Ring. *Journal of Applicable Chemistry*, **2014**, 3 (3): 126-1267.
- [30] Rambabu N, Dubey P.K., Ram. B, Balram, B. Synthesis and Antibacterial Activity of 2,3-dihydro-1H-benzo[f]chromen-1-one and 2,3-dihydro-1H-benzo[f]chromen-1-ol Derivatives. *Journal of Applicable Chemistry*, **2013**, 2 (6): 1516-1522.
- [31] Nimmala Srinivas Rao, Chepyala Kistareddy, Balram.B, Ram.B. Synthesis, Antibacterial and Antifungal Activity of New Chalcone Analogues Derived From 2-Hydroxy-Acetonaphthone. *Journal of Applicable Chemistry*, **2013**, 2 (6): 1705-1710.
- [32] Rajasekhar Narisetty, K.B. Chandrasekhar, Sandeep Mohanty, M. Rameswara Rao, B. Balram. Synthesis and Antimicrobial Evaluation of Some Novel Hydrazone Derivatives of 2,5-diflurobenzoic acid. *Journal of Applicable Chemistry*, **2013**, 2 (6): 1489-1498.
- [33] Shaik Khadar Yazdan, K. Sampath Kumar, B. Ratnabhushanam, J. V. Padmavathi, G. Krishna Kishore, K. Mohan. Synthesis of Acetophenone Chalcone Derivatives and their Antibacterial Activity. *Journal of Applicable Chemistry*, **2014**, 3 (2): 601-605.